BackSummit Therapeutics Overview
Summit Therapeutics Inc

Summit Therapeutics Target Price

Analysts' average 12-month price target for Summit Therapeutics is $27.

Get informed when a big investor buys or sells

+ Follow

Share Price

$15.61

Average Target Price

$26.8271.8% upside

6 analysts in the last 4 months

High: $38 | Low: $11.9

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-09Summit Redstone PartnersFaisal Khurshid$2560.2% upsideOpen
2026-09-08UBSDavid Dai$33111.4% upsideOpen
2026-08-25Summit Redstone PartnersJeffrey Walch$11.923.8% downsideOpen
2026-07-24Jefferies$153.9% downsideOpen
2026-07-24Stifel NicolausDara Azar$38143.4% upsideOpen
2026-07-24GuggenheimBrad Canino$38143.4% upsideOpen
2026-05-04H.C. Wainwright$2347.3% upsideOpen
2026-05-01Piper Sandler$162.5% upsideOpen
2026-02-24H.C. Wainwright$3092.2% upsideOpen
2026-01-14Piper Sandler$40156.2% upsideOpen
2025-12-17Summit Redstone PartnersEtzer Darout$1815.3% upsideOpen
2025-10-21H.C. Wainwright$40156.2% upsideOpen
2025-10-21Barclays$162.5% upsideOpen
2025-09-16Summit Redstone Partners$1316.7% downsideOpen
2025-08-19Summit Redstone PartnersKelsey Goodwin$2134.5% upsideOpen
2025-04-28H.C. Wainwright$44181.9% upsideOpen
2025-04-25Wells Fargo$3092.2% upsideOpen
2025-04-25JefferiesKelly Shi$44181.9% upsideOpen
2025-03-26Summit Redstone PartnersYigal Nochomovitz$35124.2% upsideOpen
2025-02-28Summit Redstone Partners$42169.1% upsideOpen
2024-11-04JMP SecuritiesReni Benjamin$32105% upsideOpen
2024-09-27Summit Redstone PartnersYigal Nochomovitz$2347.3% upsideOpen
2024-09-25Stifel NicolausBrad Canino$40156.2% upsideOpen
2024-09-16H.C. WainwrightMitchell Kapoor$45188.3% upsideOpen
2024-06-03Stifel NicolausBrad Canino$1410.3% downsideOpen
2024-03-25Stifel NicolausBrad Canino$848.8% downsideOpen

Summit Therapeutics (SMMT) FAQ

Summit Therapeutics posts a target price of $27. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $27 for SMMT means covering analysts, on average, see the stock 71.8% upside of $15.61 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for SMMT's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Summit Therapeutics's other metric pages and overview cover the third.